Two Sigma Advisers LP Sells 155,600 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Two Sigma Advisers LP cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 60.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 103,100 shares of the biopharmaceutical company's stock after selling 155,600 shares during the quarter. Two Sigma Advisers LP owned 0.08% of Alnylam Pharmaceuticals worth $28,356,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Cetera Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $238,000. CWM LLC increased its stake in shares of Alnylam Pharmaceuticals by 102.8% during the second quarter. CWM LLC now owns 3,492 shares of the biopharmaceutical company's stock worth $849,000 after buying an additional 1,770 shares during the period. Sequoia Financial Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 13.7% during the second quarter. Sequoia Financial Advisors LLC now owns 3,308 shares of the biopharmaceutical company's stock worth $804,000 after buying an additional 398 shares during the period. Wedmont Private Capital acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $321,000. Finally, Diversified Trust Co acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $1,210,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company's stock, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares of the company's stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,370 shares of company stock valued at $2,100,703. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY traded up $4.45 during trading on Friday, hitting $256.26. The company's stock had a trading volume of 574,959 shares, compared to its average volume of 787,885. The firm's 50 day moving average price is $269.12 and its two-hundred day moving average price is $245.29. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market capitalization of $33.05 billion, a price-to-earnings ratio of -97.81 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts' expectations of $532.91 million. During the same period last year, the firm posted $1.15 EPS. The business's revenue was down 33.3% on a year-over-year basis. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the subject of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their target price for the company from $198.00 to $370.00 in a report on Friday, August 16th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.